|
Orthologous residues
|
|
PLCG1 (human): S1248‑p, PLCG1 iso2 (human): S1249‑p, PLCG1 (mouse): S1248‑p, PLCG1 (rat): S1248‑p, PLCG1 (cow): S1249‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
Jurkat (T lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACa (human)
|
pharmacological activator of upstream enzyme
|
|
|
KINASE
|
PKCA (human)
|
pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
anti-CD3
|
|
|
|
increase
|
|
|
phorbol ester
|
anti-CD3
|
|
|
inhibit treatment-induced increase
|
Prior treatment of cells with PMA reduced OKT3-induced tyrosine phosphorylation of PLC-gamma1.
|
|
forskolin
|
anti-CD3
|
|
|
inhibit treatment-induced increase
|
Prior treatment of cells with forskolin reduced OKT3-induced tyrosine phosphorylation of PLC-gamma1
|
|
phorbol ester
|
|
|
|
increase
|
|
|
forskolin
|
|
|
|
increase
|
|
|
